Cellectar secures 'extended partnership' to support clinical trial needs

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/shironosov)
(Image: iStock/shironosov)

Related tags: Clinical trial

Cellectar Biosciences has announced a partnership with the Centre for Probe Development and Commercialization (CPDC) to establish manufacturing capacity ahead of the company’s NCI-supported Ph II trial of CLR 131.

Per the agreement, the GMP manufacturing organization, which specializes in radiopharmaceuticals, will serve as a supplier of Cellectar’s lead phospholipid drug conjugate (PDC), CLR 131.

CPDC possesses a great team and extensive experience manufacturing radiotherapeutics​,” Jim Caruso, president and CEO of Cellectar Biosciences, told us, adding that the company will provide “cost effective, high quality finished product manufacturing for the long term​.”

This partnership will provide additional supply of CLR 131 and insure sufficient manufacturing capacity to support Cellectar’s near term clinical trial needs as well as pivotal study and larger scale commercialization requirements​,” he added.

When asked how long the partnership is set to last, Caruso said “Cellectar looks forward to an extended partnership with CPDC​.”

The next steps for the partnership include ongoing process integration and enhancement.

Related news

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more